Conference Coverage

ASH releases guidelines on managing cardiopulmonary and kidney disease in SCD

Publish date: December 13, 2019

 

EXPERT ANALYSIS FROM ASH 2019

Pages

Recommended Reading

FDA approves anemia treatment for transfusion-dependent beta thalassemia patients
MDedge Hematology and Oncology
FDA approves treatment for sickle cell pain crises
MDedge Hematology and Oncology
FDA approves Givlaari for treatment of acute hepatic porphyria
MDedge Hematology and Oncology
FDA approves Oxbryta for sickle cell disease treatment
MDedge Hematology and Oncology
The clinical impact of new approvals in sickle cell, MCL
MDedge Hematology and Oncology
Fragmentation of sickle cell disease care starts in young adulthood
MDedge Hematology and Oncology
NFIX could be a target for sickle cell therapy
MDedge Hematology and Oncology
Oral arginine emerges as potential adjuvant for vaso-occlusive crisis management
MDedge Hematology and Oncology
Think twice: Choosing Wisely recommendations on testing to avoid in pediatric hematology
MDedge Hematology and Oncology
Sutimlimab boosts hemoglobin, quality of life in cold agglutinin disease
MDedge Hematology and Oncology